SparingVision Raises €44.5m For Mutation-Agnostic Eye Gene Therapy
French Biotech Tackling Retinitis Pigmentosa
A long-term, patient-centric group of investors is backing SparingVision's bid to develop a gene therapy treatment for retinitis pigmentosa that could be effective regardless of mutation.
